Special Issue

Precision Medicine in Childhood Asthma

Message from the Guest Editors

Asthma is a highly complex and heterogeneous disease. Children and adults with asthma can be stratified into distinct clinical phenotypes, the treatment of asthma has traditionally focused on a one-size-fits all approach. We believe that three major advances are poised to revolutionize the treatment of childhood asthma. The first advance is the development of new therapies that target specific molecular pathways. The second advance is the advent of molecular profiling technologies. The third advance pertains to the development of sophisticated bioinformatics tools. Towards this goal, new studies are urgently needed that embed these ground-breaking technologies into pediatric asthma cohorts and/or clinical trials.

We are pleased to invite you contribute to this Special Issue on Precision Medicine in Childhood Asthma. This Special Issue aims to highlight the application of genomics and bioinformatics to elucidate childhood asthma phenotypes, obtain mechanistic insights into disease biology, and link these to targeted therapies. We welcome original research articles and reviews.

Guest Editors

Dr. Anthony Bosco

Associate Research Scientist, Asthma & Airway Disease Research Center, the University of Arizona, Tucson, AZ 85721, USA

Dr. Anya C. Jones

Telethon Kids Institute, University of Western Australia, Perth, Australia

Deadline for manuscript submissions

closed (15 October 2022)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/83657

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

